| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9999 | Chemotherapy - non specific | Not otherwise classified, antineoplastic drugs | NA | Chemotherapy | No | In Use | ||||||
| C9087 | Cyclophosphamide (Auromedics) | Cyclophosphamide | 10mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2021 | Jan 26, 2022 | Mar 25, 2022 | No Longer Used | |
| S0172 | Chlorambucil | Leukeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1957 | Jan 1, 2002 | In Use | ||
| N/A | Zongertinib | HERNEXEOS | 60mg | Chemotherapy | Tyrosine Kinase Inhibitor | HER2 | Yes | 2025 | In Use | |||
| J9092 | Cyclophosphamide | Cyclophosphamide | 2 g | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1959 | Jan 1, 1994 | In Use | ||
| NA | Altretamine | Hexalen | 50 mg | Chemotherapy | Alkylating Agent | Triazines | Yes | 1990 | 2019 | In Use | ||
| NA | Carmustine wafer | Gliadel | 7.7mg | Chemotherapy | Alkylating Agent | Nitrosourea | No | 2012 | In Use | |||
| NA | Fedratinib Hydrochloride | Inrebic | 100mg | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Yes | 2019 | In Use | |||
| N/A | Taletrectinib | IBTROZI | 272mg | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Yes | 2025 | In Use | |||
| J9059 | Bendamustine (Baxter) | Bendamustine (Baxter) | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2022 | Jul 11, 2023 | Dec 17, 2024 | No Longer Used | |
| J9048 | Bortezomib (Fresniuskab) | Bortezomib (Fresniuskab) | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2017 | Dec 21, 2022 | In Use | ||
| NA | Uracil Mustard | Uramustine | unspecified | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 1962 | 1999 | No Longer Used | ||
| NA | Osimertinib | Tagrisso | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | In Use | |||
| NA | Pexidartinib | Turalio | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | CSF1R, KIT, FLT3 | Yes | 2019 | In Use | |||
| J9342 | Thiotepa (not otherwise specified) | Thiotepa | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2001 | Jul 9, 2025 | In Use | ||
| NA | Entrectinib | Rozlytrek | 100mg, 200mg | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Yes | 2019 | In Use | |||
| J9073 | Cyclophosphamide (Dr Reddy's) | Cyclophosphamide (Dr Reddy's) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2020 | Apr 17, 2024 | In Use | ||
| Vorasidenib | Voranigo | 10mg,40mg | Chemotherapy | IDH Inhibitor | IDH1, IDH2 | Yes | 2024 | In Use | ||||
| NA | Enasidenib mesylate | Idhifa | 100 mg | Chemotherapy | Enzyme Inhibitor | IDH2 | Yes | 2017 | In Use | |||
| J9250 | Methotrexate | Trexall | 5 mg | Chemotherapy | Antimetabolite | Folic Acid Analog | Yes | 1953 | Jan 1, 1994 | Apr 17, 2024 | No Longer Used | |
| C9065 | Romidepsin | Romidepsin | 1mg | Chemotherapy | Enzyme Inhibetor | HDAC | No | 2020 | Jan 1, 2021 | Sep 27, 2021 | No Longer Used | |
| NA | ixazomib | Ninlaro | 2.3 mg | Chemotherapy | Proteasome Inhibitor | 20S | Yes | 2015 | In Use | |||
| NA | Nilotinib | Tasigna | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2007 | In Use | |||
| J9201 | Gemcitabine | Gemzar | 200 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1996 | Jan 1, 1998 | In Use | ||
| NA | Afatinib | Gliotrif | 30 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2013 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home